Brief: Epigenomics Plans To Challenge NCD Decision And Unveils Its Next Generation Liquid Biopsy Test
21/01/2021 09:05
Jan 21 (Reuters) - EPIGENOMICS AG ECXn.DE :
* PLANS TO CHALLENGE NCD DECISION AND UNVEILS ITS NEXT
GENERATION
LIQUID BIOPSY TEST FOR COLORECTAL CANCER SCREENING
* AUTOMATED ASSAY IS HIGHLY ROBUST, PROVIDING VALID RESULTS
FOR
GREATER THAN 99% OF SAMPLES ANALYZED, AND PROVIDES A FAST, EASY
TO USE AND AFFORDABLE OPTION FOR DETECTING CRC IN A LIQUID
BIOPSY
Source text for Eikon: ID:nEQbnpm0Ha
Further company coverage: ECXn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns